Avi Hasson explains what his role is as Israel’s Chief Scientist and how his office uses the public-private partnership to fuel Israeli innovation. http://www.forbes.com/sites/gilpress/2015/07/20/how-startup-nations-innovation-catalyst-masters-the-art-of-public-private-partnership/

21-year-old Israeli Tomer Hen started mobile advertising when still at school. When he graduated from high school he had already made $250,000. His communication skills helped him to launch the Tomer Hen Mobile Marketing College. Now he is CEO of … Continue reading →

Approval has been given for the building of a 105-meter high building in downtown Jerusalem. The “Freedom Pyramid” will house a hotel, apartments and businesses. Its architect is Daniel Libeskind, who designed the Berlin Jewish Museum and NYC’s World Trade … Continue reading →

Israeli start-up Ecoppia was selected to Red Herring’s Top 100 Europe List. Red Herring selects start-ups they predict will “grow at an explosive rate”. Also, solar industry publication PV Magazine ranked Ecoppia 15th in their list of “50 Array-Changing Technologies.” … Continue reading →

A high-level Israeli trade delegation is in Japan discussing expanding business relations between the two countries. They cover medical treatments and equipment, agro-biotech, diagnostics and health IT. http://www.timesofisrael.com/israeli-delegation-in-tokyo-for-trade-talks/

In order to exploit the full potential of the offshore natural gas reserves of each country, Cyprus and Israel have agreed to expand cooperation, including pipeline and grid sharing as a means of reaching the European market. http://www.forbes.com/sites/christophercoats/2015/07/30/cyprus-continues-energy-outreach-with-israel-agreement/ http://breakingenergy.com/2015/07/29/israels-developing-relationship-with-cyprus/

Germany’s Merck will acquire cCAM Biotherapeutics, the Israeli developer of cancer immunotherapies, for an estimated $600 million. cCAM is developing CM-24, for the treatment of melanoma and certain lung, bladder, gastric, colorectal and ovarian cancers. http://www.haaretz.com/business/1.668381